Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

  title={Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.},
  author={Sara Bringhen and Alessandra Larocca and Davide Rossi and Maide Cavalli and Mariella Genuardi and Roberto Ria and Silvia Gentili and Francesca Patriarca and Chiara Nozzoli and Anna Levi and Tommasina Guglielmelli and Giulia Benevolo and Vincenzo Callea and Vincenzo Rizzo and Clotilde Cangialosi and Pellegrino Musto and Luca De Rosa and Anna Marina Liberati and Mariella Grasso and Antonietta Pia Falcone and Andrea Evangelista and Michele Cavo and Gianluca Gaidano and Mario Boccadoro and Antonio Palumbo},
  volume={116 23},
In a recent phase 3 trial, bortezomib-melphalan-prednisone-thalidomide followed by maintenance treatment with bortezomib-thalidomide demonstrated superior efficacy compared with bortezomib-melphalan-prednisone. To decrease neurologic toxicities, the protocol was amended and patients in both arms received once-weekly instead of the initial twice-weekly bortezomib infusions: 372 patients received once-weekly and 139 twice-weekly bortezomib. In this post-hoc analysis we assessed the impact of the… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 133 extracted citations

Cancer Neurology in Clinical Practice

Springer International Publishing • 2018


Publications referenced by this paper.
Showing 1-10 of 29 references

A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone ( MPR ) in elderly patients with newly diagnosed multiple myeloma [ abstract ]

A Palumbo, MA Dimopoulos, M Delforge
Blood • 2009

NCCN clinical practice guidelines in oncology: multiple myeloma.

Journal of the National Comprehensive Cancer Network : JNCCN • 2009

Peripheral neuropathy with VMP resolves in the majority of patients and shows a rate plateau [ abstract ]

PG Richardson, W Xie, C Mitsiades
Clin Lymphoma Myeloma • 2009

Similar Papers

Loading similar papers…